
WAVERLEY PHARMA – CORPORATE PRESENTATION 2020



WAVERLEY PHARMA

Forward-Looking Statements

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements and other estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's potential product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's

products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities.

SOURCE Waverley Pharma Inc.



CONFIDENTIAL

WAVERLEY PHARMA

Waverley Pharma Overview

- A specialty pharma company dedicated to the development and commercialization of safe, effective and affordable therapeutic products
- Currently focused on the oncology market in UK, Europe and North America
- Partnering with companies such as Reliance Life Sciences to develop and commercialize additional oncology products for these markets
- Carefully monitor opportunities and possible acquisitions of related pharmaceutical products in order to realize long term value

WAVERLEY PHARMA - MANAGEMENT

Larry Thiessen, President & CEO

- 28 years of pharmaceutical experience having worked for Bausch Health Companies Inc. (formerly Biovail Corporation)
- He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation
- Bachelor of Science in Biology and an Executive M.B.A.

Haaris Uddin, BSc Commerce (Honours), CPA, Chief Financial Officer

- Mr. Uddin joined Waverley Pharma August 2019
- Experience with Ernst & Young as a senior accountant, working with life science companies in both Canada and the United States (Houston, and San Francisco)

Pallav Simariya, M. Pharm. Pharmaceutical Technology, Director, Regulatory & Technical Affairs

- Joined Waverley in November 2017
- 10 years pharma experience to plan, coordinate, and drive the development and evaluation of brand & generic drug products
- Pharma experience, includes, Apotex Inc., Catalent Pharma, Cadila Pharmaceuticals

WAVERLEY PHARMA – CURRENT PRODUCTS

Generic drugs:

UK Marketed Generic Drugs: (Patents expired)

Capecitabine – is a chemotherapy drug used to treat breast cancer, gastric cancer and colorectal cancer.

Temozolomide – is a chemotherapy drug used for the treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.

Erlotinib – is a chemotherapy drug for non small cell lung cancer (NSCLC) that has spread. pancreatic cancer that has spread – alongside the chemotherapy drug gemcitabine.

UK Approved & EU Pending Approval Generic Drugs:

Bortezomib – is a chemotherapy drug used to treat multiple myeloma (patent expiry Q1 2022)

Pemetrexed – is a chemotherapy drug used to treat lung cancer (patent expiry Q3 2021)

US Filed ANDA Generic Drugs:

WAV-101 – is a chemotherapy drug; brand sales are > 1 billion USD (patent expiry Q3 2022).

WAV-102 – is a chemotherapy drug; brand sales are > 800 million USD (patent expiry Q3 2022)

In Development:


Discovery:

PARP-1 Inhibitor – small molecule drug - a new class of anticancer agents targeting DNA repair mechanism

WAVERLEY PHARMA – MARKET OVERVIEW

Leading Hospital Oncology Small Molecules

The Top 50 oncology small molecules represent 90% in value and 63% in volume of total oncology small molecules market. 36 of these molecules are not yet genericized allowing a great opportunity to develop a high value & competitive portfolio for the next decade (markets details in Annexure 1).



* Molecules already genericized

** Dispensed mainly in Retail (outpatients)



Source: IQVIA-MIDAS



CONFIDENTIAL

WAVERLEY PHARMA – MARKET OVERVIEW

EU Market by Sectors




- The EU total market is estimated at US\$ 224Bn presenting a positive growth rate of 2.3%, CAGR₂₀₁₆₋₁₈.
- The EU Hospital sector represents one third of total market value showing a growth rate of 4.7% (CAGR₂₀₁₆₋₁₈), twice the rate of the total market.
- Volume wise both EU total market and Hospital sector are stagnating, revealing that the positive value trend is driven by the successive launch of high value products, namely biotech products.

Source: IQVIA-MIDAS

WAVERLEY PHARMA – MARKET OVERVIEW

EU Market by Sectors



- Top 5 therapeutic areas account for 50% of the total EU market. Oncology is the leading therapeutic area with 15% market share (MS), having also a very positive trend (8.8%, CAGR₂₀₁₆₋₁₈), growing four times faster than the total market.
- In the EU Hospital sector, Oncology has stronger leading position reaching 28% MS, sustained by a strong positive evolution of 9.4% (CAGR₂₀₁₆₋₁₈), growing at twice the rate of the Hospital sector. In the Retail sector Oncology also has a remarkable 4th position with 7% MS and an evolution of 7.5% (CAGR₂₀₁₆₋₁₈).


Source: IQVIA-MIDAS

CONFIDENTIAL

WAVERLEY PHARMA – UK MARKET

Status of MHRA Approvals

- MHRA Approvals
 - Capecitabine – 150mg and 500mg
 - Temozolomide – 5mg, 20mg, 100mg, 140mg, 180mg and 250mg
 - Erlotinib – 25mg, 100mg and 150mg
 - Bortezomib – 1mg and 3.5mg
 - Pemetrexed – 100mg and 500mg
- Wholesale Distribution Authorization (WDA) License
- Pharmacovigilance Contract and SOPs in place
- First sales October 2018



WAVERLEY PHARMA – EU MARKET

Status of EU Approvals

Products Filed in EU Markets

- Bortezomib – 1mg & 3.5mg (Pending approval in all filed EU countries)
- Pemetrexed – 100mg & 500mg (Pending approval in all filed EU countries)

Exploring Partnerships in EU Countries

- Bortezomib – 1mg & 3.5mg
- Pemetrexed – 100mg & 500mg
- Capecitabine – 150mg & 500mg (Germany only)


WAVERLEY PHARMA – US MARKET

Status of US Approvals

FDA ANDA Review

- Both WAV-101 & WAV-102 applications accepted for filing, approval expected in Q4 2020, patent expiry expected in Q3 2022
- Negotiating for additional generic oncology products for US market

U.S. specialty injectable generics market by therapeutic use, 2014 - 2025 (USD Billion)



Source: Grandview Research

WAVERLEY PHARMA – KEY FINANCIAL INFORMATION

Capital Structure as of May 8, 2020

- Common shares issued and outstanding: 54,000,000
- Share Price: \$0.055
- Market Cap \$2,970,000

Recent Financial Highlights (\$ CAD)

- 2019 Net Revenue: \$ 1,249,683
- 2019 Net Income/(Loss) \$ (1,214,778)

Source: Grandview Research